N- (1-nButyl-4-piperidyl)methyl -3,4-dihydro-2H- 1,3 oxazino 3,2-a indole-10-carboxamide or a pharmaceutically acceptable salt thereof

Abstract: N-[(1- n Butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide and its pharmaceutically acceptable salts and their use as pharmaceuticals in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.

Description: This invention relates to a novel compound having pharmacological activity, to a process for its preparation and to its use as a pharmaceutical. EP-A-429984 (Nisshin Flour Milling Co., Ltd.) describes indole derivatives having 5-HT 3 receptor antagonist activity. European Journal of Pharmacology 146 (1988), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT 4 receptor, and that ICS 205-930, which is also a 5-HT 3 receptor antagonist, acts as an antagonist at this receptor. WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT 4 receptor antagonists in the treatment of atrial arrhythmias and stroke. EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT 4 antagonist activity. A novel, structurally distinct compound has now been discovered, which compound is an indole derivative 1,2-disubstituted by alkyleneoxy, with an azacyclic moiety. This compound has 5-HT 4 receptor antagonist activity. Accordingly, the present invention provides N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide, namely the compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein X is O; A is -(CH 2 ) 3 - ; R 1 R 2 R 3 and R 4 are hydrogen; Y is NH; Z is of formula (i): The pharmaceutically acceptable salts of the compound of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α-keto glutaric, α-glycerophosphoric, and glucose-1-phosphoric acids. Examples of pharmaceutically acceptable salts include quaternary derivatives of the compound of formula (I) which are the compound quaternised by compounds R x -T wherein R x is methyl, ethyl, n -propyl, iso -propyl, benzyl or phenethyl, and T is a radical corresponding to an anion of an acid. Suitable examples of T include halide such as chloride, bromide and iodide. Examples of pharmaceutically acceptable salts also include internal salts which are N-oxides. The compound of the formula (I), and its pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever the compound of formula (I) or a salt thereof is herein referred to. The compound of formula (I) may be prepared by conventional coupling of the indole moiety with Z. Suitable methods are as described in GB 2125398A (Sandoz Limited), GB 1593146A and EP-A-36269 (Beecham Group p.l.c.), EP-A-429984 (Nisshin Flour Milling Co.) and EP-A-328200 (Merck Sharp & Dohme Limited). Reference is also made to EP-A-501322 (Glaxo Group Limited). It will be appreciated that the (CH 2 ) r -O containing ring or R 3 /R 4 introduction/modification may be carried out before or after coupling. Aza(bi)cyclic side chain intermediates are known compounds or may be prepared according to the methods described in PCT/GB92/01519 and /01612 (SmithKline Beecham p.l.c.). The compounds of the present invention are 5-HT 4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders. They are of potential interest in the treatment of irritable bowel syndrome (IBS), in particular the diarrhoea aspects of IBS, i.e., these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS. They may also be of potential use in other gastrointestinal disorders, such as those associated with upper gut motility, and as antiemetics. In particular, they are of potential use in the treatment of the nausea and gastric symptoms of gastro-oesophageal reflux disease and dyspepsia. Antiemetic activity is determined in known animal models of cytotoxic-agent/radiation induced emesis. Specific cardiac 5-HT 4 receptor antagonists which prevent atrial fibrillation and other atrial arrhythmias associated with 5-HT, would also be expected to reduce occurrence of stroke (see A.J. Kaumann 1990, Naumyn-Schmiedeberg's Arch. Pharmacol. 342, 619-622, for appropriate animal test method). It is believed that platelet-derived 5-HT induces atrial arrhythmias which encourage atrial fibrillation and atrial disorders are associated with symptomatic cerebral and sytemic embolism. Cerebral embolism is the most common cause of ischaemic stroke and the heart the most common source of embolic material. Of particular concern is the frequency of embolism associated with atrial fibrillation. Anxiolytic activity is likely to be effected via the hippocampus (Dumuis et al 1988, Mol Pharmacol., 34, 880-887). Activity may be demonstrated in standard animal models, the social interaction test and the X-maze test. Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al ., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT 4 receptors, and hence that administration of a 5-HT 4 antagonist is of potential benefit in relieving a migraine attack. The invention also provides a pharmaceutical composition comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Such compositions are prepared by admixture and are usually adapted for enteral such as oral, nasal or rectal, or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, nasal sprays, suppositories, injectable and infusable solutions or suspensions. Sublingual or transdermal administration is also envisaged. Orally administrable compositions are preferred, since they are more convenient for general use. Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating. Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents. Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents. The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art. For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention. The invention further provides the use of the compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier in the preparation by admixture of a pharmaceutical composition for the treatment of irritable bowel syndrome, gastro-oesophagal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, the composition being for the administration of an effective amount of the compound of the formula (I) or the pharmaceutically acceptable salt thereof. In particular, the composition is for treatment of IBS or atrial arrhythmias and stroke. An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose for a 70 kg adult will normally contain 0.05 to 1000 mg for example 0.5 to 500 mg, of the compound of the invention. Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50 mg/kg/day, more usually 0.0002 to 25 mg/kg/day. No adverse toxicological effects are indicated within the aforementioned dosage ranges. The invention also provides the compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use as a 5-HT 4 receptor antagonist in the treatment of the disorders hereinbefore described. The invention also provides the use of the compound of formula (I) in the manufacture of a medicament for use as a 5-HT 4 receptor antagonist in the treatment of the disorders hereinbefore described. The following Example illustrates the preparation of the compound of formula (I); the following Description illustrates the preparation of an intermediate. Example N-[(1- n Butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide Method 1:- A stirred solution of N-chlorosuccinimide (57 mg, 0.48 mmole) in chloroform (3 ml) was treated with a solution of N-[(1- n butyl-4-piperidyl)methyl] indole-3-carboxamide (100 mg, 0.32 mmole) in chloroform (8 ml) and kept at room temperature for 2h, then treated with 3-bromo-1-propanol (0.03 ml, 0.32 mmole). After stirring for 16h, more 3-bromo-1-propanol (0.03 ml, 0.32 mmole) was added. The mixture was stirred at room temperature for a further 3h, then treated with excess 10% Na 2 CO 3 solution and extracted with chloroform. The extract was dried (Na 2 SO 4 ) and concentrated in vacuo to leave a yellow oil, which was dissolved in acetone (10 ml), treated with anhydrous potassium carbonate (130 mg, 0.96 mmole) and stirred at room temperature for 16h. The mixture was concentrated in vacuo , the residue treated with 10% Na 2 CO 3 solution (10 ml) and extracted with chloroform. The extract was dried (Na 2 SO 4 ) and concentrated in vacuo to leave a yellow oil, which was chromatographed, initially on silica gel eluting with chloroform/methanol (19:1), then on basic alumina eluting with ethyl acetate. The colourless oil obtained crystallised from ether to afford the title compound as a white solid (20 mg, 17%) mp 110-113°C. 1 H NMR (CDCl 3 ) δ: 8.34 (d,1H), 7.05-7.30 (m,3H), 6.55 (t,1H), 4.53 (t,2H), 4.10 (t,2H), 3.33 (t,2H), 2.90-3.05 (m,2H), 2.25-2.45 (m,4H), 1.90-2.25 (m,2H), 1.20-1.85 (m,9H), 0.92 (t,3H). MS (CI) MH + 370. Method 2:- A stirred suspension of N-[(1- n butyl-4-piperidyl)methyl] indole-3-carboxamide (120g, 0.38 mole) in chloroform (2 L) under nitrogen at room temperature was treated with freshly distilled 3-bromo-1-propanol (69 ml, 0.77 mole) followed by the portionwise addition of dry N-chlorosuccinimide (55g, 0.42 mole) over 5 minutes. The resulting yellow solution was stirred for 2.5h, then treated with 1M HCl in ether (15 ml, 0.015 mole). A moderate exotherm occurred and the reaction colour changed to orange. After a further 2h the mixture was treated with 10% Na 2 CO 3 solution (700 ml) and the chloroform layer separated, dried (Na 2 SO 4 ) and concentrated in vacuo to leave a thick red oil. This was treated with acetone (1.5 L) and anhydrous potassium carbonate (130g, 0.95 mole), then stirred at room temperature for 18h. The reaction mixture was concentrated in vacuo and the residue treated with water (1 L) and extracted with ethyl acetate (1 L). On standing a solid began crystallising from the ethyl acetate extract. After 2h at 8°C this was filtered off and dried to afford 51.7g of the title compound (E3) as a beige solid. The mother liquors were extracted with 1M HCl acid (800 ml), the acid extract then basified with K 2 CO 3 and extracted with chloroform (2 x 700 ml). The combined chloroform extracts were dried (Na 2 SO 4 ), concentrated in vacuo and the residue chromatographed on silica gel eluting with chloroform/methanol (96:4). A yellow oil was obtained which upon trituration with ether gave a further 21.3g of title compound as a white solid. Conversion to the hydrochloride salt and recrystallisation from ethanol/60-80 petrol gave a white solid mp 254-256 °C dec. HCl salt - 1 H NMR (D 2 O) δ: 7.90 (d,1H), 6.88-7.20 (m,3H), 4.35 (br t,2H), 3.70 (br t,2H), 3.40 (br d,2H), 3.20 (br d,2H), 2.9 (br t,2H), 2.65(br t,2H), 2.12 (br t,2H), 1.20-1.90 (m,9H), 0.87 (t,3H). Elemental analysis obtained was as follows: Theory Found Carbon 65.09 64.76, 64.75 Hydrogen 7.95 7.73, 7.77 Nitrogen 10.35 10.35, 10.36 Description (intermediate for Example) a) N-(1- n Butyl-4-piperidyl)methylamine A stirred solution of isonipecotamide (70g, 0.55 mole) and 1-bromobutane (58.8 ml, 0.55 mole) in ethanol (700 ml) was treated with anhydrous potassium carbonate (152g, 1.10 mole) and heated under reflux for 3h. The mixture was allowed to cool, then filtered and the filtrate concentrated under vacuum. The residual oil was dissolved in chloroform (400 ml) and washed with water (1 x 300 ml), then dried (Na 2 SO 4 ) and concentrated under vacuum to leave a yellow oil (77.5g). This oil was mixed thoroughly with phosphorus pentoxide (75g) and the mixture heated at 160-180°C under nitrogen for 2.5h with gentle stirring. The reaction mixture was allowed to cool, then treated with water (500 ml). When the solid mass had dissolved, the solution was basified by addition of solid K 2 CO 3 and extracted with ethyl acetate (2x400 ml). The combined extracts were dried (Na 2 SO 4 ) and concentrated in vacuo to leave a brown oil (78g). This was dissolved in dry ether (400 ml) and added dropwise over 30 minutes to a stirred suspension of lithium aluminium hydride (25g, 0.66 mole) in ether (200ml) at 0°C under nitrogen. When addition was complete, the mixture was allowed to warm upto room temperature and stir for 18h. It was recooled to 0°C and treated cautiously with water (25ml), 10% NaOH solution (25 ml) and water again (75ml). The mixture was filtered through kieselguhr and the filtrate concentrated in vacuo to leave a brown oil, which was distilled under vacuum to afford the title compound as a colourless oil (66g, 71 %) bp 96-99°C at 3 mm Hg. 1 H NMR (CDCl 3 ) δ: 2.90-3.02(m,2H), 2.58(d,2H), 2.25-2.38(m,2H), 1.65-2.00(m,4H), 1.08-1.58(m,9H), 0.92(t,3H). b) N-[(1- n Butyl-4-piperidyl)methyl] indole-3-carboxamide To a stirring solution of indole-3-carboxylic acid (1g) in dichloromethane (20 ml) at 0°C under nitrogen was added oxalyl chloride (0.81 ml) and dry dimethylformamide (3 drops). After 3 hours, the solvents were evaporated under reduced pressure. A portion of the residual acid chloride (420 mg) was dissolved in dichloromethane (12 ml) and added dropwise to a solution of N-(1- n butyl-4-piperidyl)methylamine (400 mg) in dichloromethane (12 ml) followed by triethylamine (0.36 ml). After stirring at ambient temperature overnight, the reaction mixture was washed with saturated NaHCO 3 , and the organic phase was dried (Na 2 SO 4 ). The solvent was evaporated under reduced pressure and the residue recrystallised from ethyl acetate to give the title compound (467 mg, 64%). 1 H NMR (CDCl 3 ) 250 MHz δ: 9.29 (br s,1H), 8.05-7.9 (m,1H), 7.81 (d,1H), 7.55-7.4 (m,1H), 7.39-7.2 (m,2H), 6.28 (br s,1H), 3.39 (t,2H), 3.0 (br d,2H), 2.45-2.25 (m,2H), 2.1-1.1 (m,11H), 0.9 (t,3H). 5-HT 4 RECEPTOR ANTAGONIST ACTIVITY 1) Guinea pig colon Male guinea-pigs, weighing 250-400g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3cm long, are obtained from the distal colon region. These are suspended under a 0.5g load in isolated tissue baths containing Krebs solution bubbled with 5% CO 2 in O 2 and maintained at 37°C. In all experiments, the Krebs solution also contains methiothepin 10 -7 M and granisetron 10 -6 M to block effects at 5-HT 1 , 5-HT 2 and 5-HT 3 receptors. After construction of a simple concentration-response curve with 5-HT, using 30s contact times and a 15min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10 -9 M approx). The tissue is then alternately dosed every 15min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative 5-HT 4 receptor antagonist are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, pIC 50 values are determined, being defined as the -log concentration of antagonist which reduces the contraction by 50%. A compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT 4 receptor antagonist. The compound was generally active in the range of concentrations of the order of pIC 50 =7 or more. 2) Piglet Atria The compound was tested in the piglet spontaneous beating screen (Naunyn-Schmiedeberg's Arch. Pharmacol 342, 619-622). pK B (-log 10 K B ) value for the compound of the Example was 10.05. 3) Rat oesophagus Rat oesophageal tunica muscularis mucosae is set up according to Baxter et. al . Naunyn-Schmiedeberg's Arch. Pharmacol., 343, 439-446 (1991). The inner smooth muscle tube of the muscularis mucosae is isolated and mounted for isometric tension recording in oxygenated (95% O 2 /5% CO 2 ) Tyrodes solution at 37°C. All experiments are performed in pargyline pre-treated preparations (100µM for 15 min followed by washout) and in the presence of cocaine (30µM). Relaxant responses to 5-HT are obtained after pre-contracting the oesophagus tissue with carbachol (3µM). 4) 5-HT-induced motility in dog gastric pouch The compound is tested for inhibition in the in vivo method described in "Stimulation of canine motility by BRL 24924, a new gastric prokinetic agent", Bermudez et al , J. Gastrointestinal Motility, 1990, 2(4), 281-286. IN VIVO TESTING FOR ANXIOLYTIC ACTIVITY Social Interaction Test in Rats Rats (male, Sprague Dawleys, Charles River, 250-300g) are housed in groups of eight in a holding room for 5 days. They are then housed singly in a room adjacent to the experimental room for 4 days prior to the experimental day. On the experimental day rats are administered vehicle, test compound or a benzodiazepine anxiolytic, chlordiazepoxide, p.o. in pairs (n=8-16), at 15 minute intervals beginning at 10.00 a.m. 30 mins. later they are placed with a weight matched pair-mate (encountered for the first time) in the social interaction box in a separate room. The box is made of white perspex 54 cm x 37 cm x 26 cm with a transparent perspex front side and no lid. The floor is divided up into 24 squares and the box is brightly lit (115 lux). Active social interactive behaviours (grooming, sniffing, climbing over or under, following, biting, mounting and boxing) are scored blind for the next 15 min by remote video monitoring to give total interaction scores. The number of squares crossed by each rat is also scored and summed. After the end of each test the box is carefully wiped. The compound of the Example increased total interaction scores over the dose range 0.01 10 mg/kg p.o.

Claims: N-[(1- n Butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof. N-[(1- n Butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide. A pharmaceutically acceptable salt according to claim 1, which is an acid addition salt with hydrochloric, hydrobromic, boric, phosphoric, or sulphuric acid, or with a pharmaceutically acceptable organic acid. A pharmaceutically acceptable salt according to claim 1, which is an acid addition salt with hydrochloric, hydrobromic, boric, phosphoric, sulphuric, acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α-keto glutaric, α-glycerophosphoric, or glucose-1-phosphoric acid. The hydrochloride salt of N-[(1- n Butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide. A pharmaceutical composition comprising N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof, according to any of claims 1 to 5, and a pharmaceutically acceptable carrier. A composition according to claim 6 being a unit dose for a 70 kg adult containing 0.05 to 1000mg of a compound according to any of claims 1 to 5. A composition according to claim 7 being a unit dose for a 70 kg adult containing 0.5 to 500mg of a compound according to any of claims 1 to 5, A composition according to any of claims 6, 7 or 8, prepared by admixture and adapted for oral administration. A composition according to claim 9 in the form of a tablet or capsule. N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof, according to any of claims 1 to 5, for use as an active therapeutic substance. N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof, according to claim 11, for use as a 5-HT 4 receptor antagonist in the treatment of irritable bowel syndrome, gastro-oesophagal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals. N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof, according to claim 11, for use as a 5-HT 4 receptor antagonist in the treatment of atrial arrhythmias and stroke in mammals. N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof, according to claim 11, for use as a 5-HT 4 receptor antagonist in the treatment of atrial arrhythmias and stroke in humans. N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof, according to claim 11, for use as a 5-HT 4 receptor antagonist in the treatment of urinary incontinence. The use of N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide in the manufacture of a medicament for use as a 5-HT 4 receptor antagonist in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders. The use of N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide in the manufacture of a medicament for use as a 5-HT 4 receptor antagonist in the treatment of irritable bowel syndrome, gastro-oesophagal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals. The use of N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or a pharmaceutically acceptable salt thereof, as defined in any of claims 1 to 5, and a pharmaceutically acceptable carrier in the preparation by admixture of a pharmaceutical composition as defined in claim 6, wherein the pharmaceutical composition is for the treatment of irritable bowel syndrome, gastro-oesophagal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, and wherein the pharmaceutical composition is for administration of an effective amount of the N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or the pharmaceutically acceptable salt thereof. The use according to claim 18, wherein the pharmaceutical composition is a unit dose for a 70 kg adult containing 0.5 to 500mg of a compound according to any of claims 1 to 5. The use according to claim 18 or 19, wherein the pharmaceutical composition is a unit dose for administration 1 to 3 times a day in the range of 0.0002 to 25 mg/kg/day. The use according to claim 18, 19 or 20, wherein the pharmaceutical composition is adapted for oral administration. The use according to claim 21, wherein the pharmaceutical composition is in the form of a tablet or capsule. The use according to claim 17, 18, 19, 20, 21 or 22, wherein the medicament or the pharmaceutical composition is for the treatment of atrial arrhythmias and stroke in mammals. The use according to claim 17, 18, 19, 20, 21 or 22, wherein the medicament or the pharmaceutical composition is for the treatment of atrial arrhythmias and stroke in humans. The use according to claim 17, 18, 19, 20, 21 or 22, wherein the medicament or the pharmaceutical composition is for the treatment of irritable bowel syndrome in humans. The use of N-[(1- n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide in the manufacture of a medicament for use as a 5-HT 4 receptor antagonist in the treatment of urinary incontinence.

Inventors: GASTER LARAMIE MARY, WYMAN PAUL ADRIAN, GASTER, LARAMIE MARY, WYMAN, PAUL ADRIAN, GASTER, Laramie Mary, GlaxoSmithKline, Wyman, Paul Adrian, GlaxoSmithKline
Applicants: SMITHKLINE BEECHAM PLC
Application year: 1993
Main classification: C07D498
IPC codes: C07D498